Aspirin for DVT Prophylaxis: Efficacy and Limitations
Introduction to Aspirin Efficacy
- The National Comprehensive Cancer Network (NCCN) guidelines state that aspirin is not considered effective for venous thromboembolism (VTE) prophylaxis in most clinical settings 1
- Aspirin (81-325 mg/d) is only considered an option for VTE prophylaxis in a select group of patients with multiple myeloma who are at low risk for VTE (≤1 individual or multiple myeloma risk factor) 3, 4
Evidence from Clinical Studies
- The Women's Health study found no significant differences in the incidence of VTE between healthy women randomly assigned to aspirin (100 mg) or placebo on alternate days 1
- The American College of Cardiology/American Heart Association recommends a daily aspirin dose of 81 mg (range 75-100 mg) for cardiovascular indications 5, 6
Patient Populations and Aspirin Use
- For patients with multiple myeloma at low risk for VTE, aspirin 81-325 mg daily (not twice daily) may be considered 3, 4
- The NCCN guidelines suggest that low molecular weight heparins (LMWH) are generally preferred over aspirin for DVT prophylaxis in high-risk patients 1
Clinical Recommendations
- Intermittent pneumatic compression (IPC) devices are recommended for patients who cannot receive anticoagulation, as they have no associated bleeding risk 1
- Aspirin cannot be recommended for VTE prophylaxis or extended treatment of VTE in patients with cancer 1, 3
- The American College of Cardiology recommends against relying on aspirin as the sole agent for DVT prophylaxis in most hospitalized patients or those with significant VTE risk factors 1, 3